Full-Time

Sr. Associate Scientist

Upstream Polysaccharide Process Development

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$111k - $128kAnnually

Mid, Senior

San Carlos, CA, USA

Position requires onsite presence in San Carlos, California.

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Python
R
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • MSc in Chemical/Biochemical Engineering, Biotechnology, or similar degree with a minimum of 3 years of relevant industry experience, or BSc with a minimum of 5 years of relevant industry experience.
  • Experience in handling microorganisms with proper aseptic techniques to perform upstream processing related work in flasks/bioreactors.
  • Hands-on experience and theoretical understanding of key processing operations such as microbial culture, fermentation process, microbial media, and process optimization and relevant analytical technologies; experience with depth filtration, continuous centrifugation is a plus.
  • Develop and optimize scripts for instrumentation, including Ambr® systems, to enhance efficiency and automate processes, leveraging programming languages such as Python or R is a plus.
  • Experience with Design of Experiments (DoE) principles and DoE software.
  • Process characterization experience is a plus.
  • Cell banking expertise, colony selection and genetic analysis of recombinant strains is a plus.
  • Proficiency with computer programs such as Microsoft Excel, Word, PowerPoint, Visio and JMP.
  • Working knowledge of GMP requirements.
  • Proven ability to succeed in a cross-functional team environment, effectively managing multiple projects and contributing to team outcomes.
  • Strong interpersonal skills, with excellent written and verbal communication abilities.
Responsibilities
  • Support in study design, execute, and analyze experiments for upstream polysaccharide for bacterial fermentation (BSL2) and vaccine production processes.
  • Execute experiments to develop the upstream process parameters (e.g., media, feed, pH, temperature, dissolved oxygen, agitation, etc.) and to enhance product yield, quality, and consistency.
  • Perform microbiology related work including plating, colony selection, Gram staining and cell enumeration on microscope.
  • Perform fermentation vessel assembly and script writing for process automation and execute fermentation experiment in shake-flask and lab scale bioreactors.
  • Prepare media and buffer as needed for experiments.
  • Operate and maintain instrumentation for bacterial fermentation and primary recovery (centrifugation, filtration, etc.) of bacterial polysaccharides utilizing aseptic techniques.
  • Support analytical method execution including optical density, residual metabolites and polysaccharide concentration and other relevant analytical techniques.
  • Assist in executing late-stage process development studies including process characterization.
  • Keep accurate and current records of research and/or project related activities in laboratory notebooks and Electronic Lab Notebook.
  • Prepare and review protocol, technical reports, SOPs, and batch records.
  • Present and communicate scientific data and results to internal stakeholders.
  • Be an outstanding teammate and collaborate effectively with downstream, analytical, and manufacturing teams within Polysaccharide Development and Manufacturing team to ensure seamless technology transfer and process integration.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to improve global health outcomes, particularly for vulnerable populations.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

24%

1 year growth

63%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Vaxcyte's VAX-24 has FDA Breakthrough Therapy designation, expediting its development.
  • Recent $1.5 billion public offering indicates strong investor confidence in Vaxcyte.
  • Growing demand for pneumococcal vaccines in emerging markets boosts Vaxcyte's market potential.

What critics are saying

  • Competition from Pfizer's Prevnar 20 could impact Vaxcyte's market share.
  • Reliance on XpressCF™ platform poses risks if technical challenges arise.
  • Emergence of new bacterial strains may reduce current vaccine effectiveness.

What makes Vaxcyte unique

  • Vaxcyte uses a proprietary cell-free protein synthesis platform, XpressCF™, for vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae.
  • Vaxcyte's vaccines aim to combat bacterial infections with broad-spectrum efficacy.

Help us improve and share your feedback! Did you find this helpful?